Luspatercept Treatment Guidelines for Myelodysplastic Syndrome

Introduction to Luspatercept Treatment

• The National Comprehensive Cancer Network recommends luspatercept only for patients with very low- to intermediate-risk myelodysplastic syndrome (MDS) with ring sideroblasts (≥15%) or SF3B1 mutation, and who are transfusion-dependent 1, 2, 4, 5, 9
• Luspatercept should be used only after erythropoietin-stimulating agent (ESA) failure or ineligibility, as second-line therapy 1, 2, 4, 6, 7

Risk Stratification and Treatment Pathway

• Patients with pancytopenia, including thrombocytopenia, may have higher-risk MDS, requiring careful risk stratification to determine the appropriate treatment sequence 1, 2
• The International Prognostic Scoring System-Revised (IPSS-R) risk category is essential for determining the treatment plan, with luspatercept only approved for very low-, low-, or intermediate-risk disease 1, 9

Luspatercept Indication Criteria

• The American Society of Hematology and the National Comprehensive Cancer Network list luspatercept as a Category 1 preferred option for patients with ring sideroblasts (≥15%) or SF3B1 mutation, and serum erythropoietin (EPO) ≤500 mU/mL 1
• Luspatercept is not indicated as first-line therapy; ESAs remain the preferred first-line treatment for anemia in lower-risk MDS without del(5q) 2, 4, 8

Appropriate Treatment Algorithm

• For lower-risk MDS, the treatment sequence should be: first-line ESAs, followed by luspatercept only after documented ESA failure, if the patient has ring sideroblasts or SF3B1 mutation 1, 2, 4, 8
• For higher-risk MDS, azacitidine is the standard of care, preferably as a bridge to allogeneic hematopoietic cell transplant 1, 2, 4, 7

Critical Missing Information

• Essential diagnostic information, including ring sideroblast percentage, SF3B1 mutation status, IPSS-R risk category, serum EPO level, and prior ESA trial and response, is necessary to determine luspatercept appropriateness 1, 2, 4, 8, 9

Safety and Efficacy Profile

• Luspatercept has demonstrated a favorable safety profile, with most common adverse events being fatigue, asthenia, dizziness, and diarrhea, predominantly in the first 4 cycles 1, 2
• Response to luspatercept typically occurs within 8 months of treatment initiation, with 38% transfusion independence ≥8 weeks in the MEDALIST trial 1, 2